Skip to main content
Ambu logo

Ambu — Investor Relations & Filings

Ticker · AMBU ISIN · DK0060946788 LEI · 5299008W2A69WX355710 CO Manufacturing
Open in API
Filings indexed 1,332 across all filing types
Latest filing 2019-08-22 Earnings Release
Country DK Denmark
Listing CO AMBU

About Ambu

https://www.ambu.com

Ambu is a global medical technology company that develops, manufactures, and markets single-use medical devices. A pioneer and market leader in single-use endoscopy, the company provides a broad portfolio of solutions for healthcare professionals across various clinical areas, including endoscopy, anesthesia, and patient monitoring. Its key products include the aScope™ line of single-use flexible endoscopes for pulmonology, gastroenterology, and urology, as well as video laryngoscopes. Ambu's solutions are designed to improve patient safety by eliminating the risk of cross-contamination associated with reusable devices, while also enhancing workflow efficiency in clinical environments by ensuring sterile, high-quality equipment is always available.

Recent filings

Filing Released Lang Actions
Ambu A/S: Interim report for Q3 2018/19
Earnings Release Classification · 95% confidence The document is a short announcement (2,700 characters) regarding Q3 financial results and a revision of financial guidance. It explicitly mentions an 'Attachment' containing the full company announcement, which aligns with the 'Menu vs Meal' rule for a Report Publication Announcement (RPA). Q3 2019
2019-08-22 English
Ambu A/S: Delårsrapport for 3. kvartal 2018/19
Earnings Release Classification · 95% confidence The document is a short announcement (under 3,000 characters) from Ambu A/S regarding their Q3 financial results, strategic changes in the US market, and updated financial guidance. It explicitly mentions a conference call and includes a link to an attached file titled 'Selskabsmeddelelse nr. 14 2018_19'. According to the 'Menu vs Meal' rule, since this is a short announcement providing highlights and pointing to an attached report, it is classified as a Report Publication Announcement (RPA). Q3 2019
2019-08-22 Danish
Ambu A/S: Delårsrapport for 3. kvartal 2018/19
Earnings Release Classification · 95% confidence The document is a short announcement (under 3,000 characters) from Ambu A/S regarding their Q3 financial results, strategic changes in the US market, and updated financial guidance. It explicitly mentions a conference call and includes a link to an attached file titled 'Selskabsmeddelelse nr. 14 2018_19'. According to the 'Menu vs Meal' rule, since this is a short announcement providing highlights and pointing to an attached report, it is classified as a Report Publication Announcement (RPA). Q3 2019
2019-08-22 Danish
Ambu A/S: Delårsrapport for 3. kvartal 2018/19
Earnings Release Classification · 95% confidence The document is a short announcement (under 3,000 characters) from Ambu A/S regarding their Q3 financial results, strategic changes in the US market, and updated financial guidance. It explicitly mentions a conference call and includes a link to an attached file titled 'Selskabsmeddelelse nr. 14 2018_19'. According to the 'Menu vs Meal' rule, since this is a short announcement providing highlights and pointing to an attached report, it is classified as a Report Publication Announcement (RPA). Q3 2019
2019-08-22 Danish
Ambu A/S: Delårsrapport for 3. kvartal 2018/19
Earnings Release Classification · 95% confidence The document is a short announcement (under 3,000 characters) from Ambu A/S regarding their Q3 financial results, strategic changes in the US market, and updated financial guidance. It explicitly mentions a conference call and includes a link to an attached file titled 'Selskabsmeddelelse nr. 14 2018_19'. According to the 'Menu vs Meal' rule, since this is a short announcement providing highlights and pointing to an attached report, it is classified as a Report Publication Announcement (RPA). Q3 2019
2019-08-22 Danish
Ambu A/S: Delårsrapport for 3. kvartal 2018/19
Regulatory Filings Classification · 99% confidence The document text discusses solid organic growth (10%), EBIT margin (20.1%), product pipeline updates (ENT scopes approved, duodenoscope planned), and a strategic decision to switch to direct sales in the US pulmonology market, leading to revised financial expectations for 2018/19 and 2019/20. It explicitly mentions a conference call scheduled for August 22, 2019, to discuss these results. The content strongly suggests the release of periodic financial results and management commentary. Since it provides key highlights and management discussion rather than the full, detailed financial statements (which would be an IR or 10-K), it aligns best with an Earnings Release (ER). The presence of contact information for Investor Relations and the announcement of a conference call further supports this. The document length is short (2779 chars) and it mentions an attached file, but the core content is the summary of quarterly performance and strategic changes, making ER more specific than RPA or RNS.
2019-08-22 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.